JPMORGAN CHASE & CO - AMICUS THERAPEUTICS INC ownership

AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 221 filers reported holding AMICUS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of AMICUS THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$158,194,657
-6.3%
13,009,429
-3.2%
0.02%
-5.6%
Q2 2023$168,836,431
+10.9%
13,442,391
-2.1%
0.02%
-5.3%
Q1 2023$152,305,000
+91975.0%
13,733,485
+1.4%
0.02%
-13.6%
Q4 2022$165,414
-99.9%
13,547,368
-5.5%
0.02%
+4.8%
Q3 2022$149,685,000
-12.1%
14,337,705
-9.6%
0.02%
-12.5%
Q2 2022$170,381,000
+15.7%
15,864,107
+2.0%
0.02%
+33.3%
Q1 2022$147,275,000
-16.9%
15,551,816
+1.4%
0.02%
-10.0%
Q4 2021$177,222,000
+21.4%
15,343,828
+0.4%
0.02%
+11.1%
Q3 2021$145,954,000
+14.0%
15,283,058
+15.0%
0.02%
+20.0%
Q2 2021$128,081,000
+9.1%
13,286,436
+11.8%
0.02%
-6.2%
Q1 2021$117,373,000
-39.9%
11,879,824
+40.4%
0.02%
-44.8%
Q4 2020$195,317,000
+67.1%
8,458,917
+1.9%
0.03%
+45.0%
Q3 2020$116,874,000
-3.6%
8,300,766
+3.2%
0.02%
-13.0%
Q2 2020$121,298,000
+97.0%
8,043,691
+20.7%
0.02%
+64.3%
Q1 2020$61,575,000
+62.2%
6,664,006
+71.0%
0.01%
+100.0%
Q4 2019$37,951,000
+421.8%
3,896,430
+329.7%
0.01%
+600.0%
Q3 2019$7,273,000
-29.6%
906,685
+5.4%
0.00%
-50.0%
Q2 2019$10,327,000
-14.1%
860,619
-2.7%
0.00%0.0%
Q1 2019$12,023,000
+40.1%
884,107
-1.3%
0.00%0.0%
Q4 2018$8,584,000
-27.3%
896,080
-8.2%
0.00%0.0%
Q3 2018$11,806,000
-18.6%
976,456
+5.1%
0.00%
-33.3%
Q2 2018$14,511,000
-2.0%
929,045
-5.6%
0.00%0.0%
Q1 2018$14,800,000
+3.9%
984,023
-0.6%
0.00%0.0%
Q4 2017$14,251,000
-23.2%
990,360
-21.5%
0.00%
-25.0%
Q3 2017$18,551,000
+43.7%
1,262,000
-1.5%
0.00%
+33.3%
Q2 2017$12,906,000
+23.5%
1,281,633
-12.6%
0.00%
+50.0%
Q1 2017$10,452,000
+48.0%
1,465,914
+3.2%
0.00%0.0%
Q4 2016$7,063,000
+110.3%
1,421,086
+213.1%
0.00%
+100.0%
Q3 2016$3,358,000
-38.0%
453,851
-54.3%
0.00%0.0%
Q2 2016$5,420,000
-43.7%
992,689
-12.8%
0.00%
-50.0%
Q1 2016$9,619,000
+8.4%
1,138,342
+24.4%
0.00%0.0%
Q4 2015$8,874,000
+46.5%
914,799
+111.3%
0.00%0.0%
Q3 2015$6,058,000
+119.7%
433,039
+70.9%
0.00%
+100.0%
Q1 2015$2,758,000
+335.0%
253,449
-6.8%
0.00%
Q2 2013$634,000271,8110.00%
Other shareholders
AMICUS THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Palo Alto Investors LP 10,524,022$127,972,10812.11%
Perceptive Advisors 27,692,917$336,745,87011.23%
Redmile Group, LLC 16,944,621$206,046,5919.80%
Finepoint Capital LP 1,489,025$18,106,5449.02%
CM Management, LLC 450,000$5,472,0005.81%
Avoro Capital Advisors LLC 27,400,000$333,184,0005.20%
MPM BioImpact LLC 716,139$8,708,2502.32%
Artal Group S.A. 4,062,567$49,4012.12%
SECTORAL ASSET MANAGEMENT INC 803,464$9,770,1221.90%
GREAT POINT PARTNERS LLC 857,000$10,421,1201.90%
View complete list of AMICUS THERAPEUTICS INC shareholders